AUS
NZ
UK
CA
USA
IND
On July 24, 2026, CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced the immediate appointment of Dr. Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director. Dr. Fuchs's term will continue until the company’s 2029 annual stockholders meeting, underscoring CytomX’s commitment to enhancing its governance and board expertise.
Key Points
- NASDAQ ticker: CTMX
- Dr. Charles Fuchs appointed to Board of Directors effective July 24, 2026
- Granted option to purchase 118,000 shares of common stock at closing price on July 24, 2026, vesting monthly over three years
- Receives standard non-employee director compensation and indemnification agreement per company policy
Dr. Charles Fuchs Joins CytomX Board for Three-Year Term
CytomX Therapeutics confirmed that Dr. Charles Fuchs, M.D., M.P.H., joined its Board of Directors as a Class II director effective July 24, 2026. His term is set to expire at the 2029 annual stockholders meeting. This strategic appointment supports the South San Francisco-based biopharmaceutical company’s ongoing efforts to strengthen governance and board-level expertise within oncology and immunotherapy sectors.
The announcement did not include detailed biographical information about Dr. Fuchs or specific qualifications that influenced his selection. The Class II director role is part of CytomX’s staggered board system designed to maintain stability and continuity in board governance across annual elections.
Equity Incentive Award Granted to New Director
Upon joining the Board, Dr. Fuchs was granted an option to purchase 118,000 shares of CytomX common stock under the company’s 2015 Equity Incentive Plan. The exercise price matches the closing stock price on July 24, 2026, the effective date of his appointment. This equity award aligns Dr. Fuchs’s interests with those of shareholders, promoting long-term value creation.
The stock option vests monthly over a three-year period, with 1/36th of the shares exercisable on each monthly anniversary, contingent upon Dr. Fuchs’s continued service. This vesting schedule is consistent with industry standards for director equity compensation and incentivizes sustained board engagement.
Standard Compensation and Indemnification Agreement
Dr. Fuchs will receive CytomX’s standard non-employee director compensation package, although specific financial details were not disclosed. This package typically includes cash retainers, meeting fees, and equity components consistent with other non-employee directors.
Additionally, CytomX will enter into an indemnification agreement with Dr. Fuchs, following the company’s established policy. This agreement, previously filed as Exhibit 10.16 to the company’s Form S-1 on August 28, 2015, protects directors from certain legal liabilities arising from their board duties.
No Conflicts or Related-Party Transactions Reported
The filing confirms that since the start of CytomX’s last fiscal year, there have been no transactions exceeding $120,000 involving Dr. Fuchs in which he had a direct or indirect material interest. This assures investors of the absence of conflicts of interest or related-party dealings linked to his appointment.
Furthermore, there are no special arrangements or understandings between Dr. Fuchs and CytomX or any other parties regarding his board appointment, indicating the selection followed standard governance procedures.
Corporate Governance and Regulatory Disclosures
CytomX Therapeutics, headquartered at 151 Oyster Point Boulevard, Suite 400, South San Francisco, California, is listed on the Nasdaq Global Select Market under ticker CTMX (Commission File Number 001-37587). The appointment of Dr. Fuchs was disclosed via a current report filed with the Securities and Exchange Commission on July 27, 2026.
The company’s 2015 Equity Incentive Plan governs the equity awards granted to directors, officers, and employees, ensuring alignment with shareholder interests and compliance with regulatory standards.
Board Structure and Succession Planning
Dr. Fuchs’s designation as a Class II director reflects CytomX’s staggered board structure, where directors serve overlapping three-year terms expiring in different years. This approach fosters board continuity and institutional knowledge, reducing the risk of abrupt changes in governance.
His term expiring at the 2029 annual meeting supports medium-term strategic oversight and aligns with best practices favored by institutional investors and proxy advisors.
SEC Compliance and Filing Details
The company complied with SEC disclosure requirements by filing the current report within three days of Dr. Fuchs’s appointment. The report, signed by Christopher W. Ogden, Senior Vice President and Chief Financial Officer, addresses Item 5.02 concerning director appointments and compensatory arrangements.
This comprehensive disclosure enhances transparency and investor confidence regarding the board change.
Investor Implications of Board Appointment
Board appointments are critical governance events that can influence corporate strategy and oversight. Dr. Fuchs’s addition brings an experienced perspective potentially valuable to CytomX’s oncology and immunotherapy initiatives.
While the immediate impact on CytomX’s stock price is not specified, investors may evaluate Dr. Fuchs’s professional background, governance experience, and potential contributions to the company’s strategic direction.
